Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites
Authors:
- Barbara M.A. van Vugt-LussenburgBVBarbara M.A. van Vugt-Lussenburg
- Tineke ZeldenthuisTZTineke Zeldenthuis
- Jon S.B. de VliegerJVJon S.B. de Vlieger
- Jan N.M. CommandeurJCJan N.M. Commandeur
- Nico P.E. VermeulenNVNico P.E. Vermeulen
- 1 January 2008
- journal article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 171 (1) , 96-107
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Identification of Critical Residues in Novel Drug Metabolizing Mutants of Cytochrome P450 BM3 Using Random MutagenesisJournal of Medicinal Chemistry, 2007
- Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3Biochemical and Biophysical Research Communications, 2006
- Future of ToxicologyMetabolic Activation and Drug Design: Challenges and Opportunities in Chemical ToxicologyChemical Research in Toxicology, 2006
- Fulminant drug-induced hepatic failure leading to death or liver transplantation in SwedenScandinavian Journal of Gastroenterology, 2005
- Stable-Isotope Trapping and High-Throughput Screenings of Reactive Metabolites Using the Isotope MS SignatureAnalytical Chemistry, 2004
- P450 BM3: the very model of a modern flavocytochromeTrends in Biochemical Sciences, 2002
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the food and drug administration as adverse reactionsHepatology, 1995
- Mass spectrometry in the analysis of glutathione conjugatesJournal of Mass Spectrometry, 1993
- Agranulocytosis during treatment with clozapineEuropean Journal of Clinical Pharmacology, 1977